LDR | |
01132cam a2200289Ia 4500 |
001 |
|
010389417 |
003 |
|
MiAaHDL |
005 |
|
20110718000000.0 |
006 |
|
m d |
007 |
|
cr bn ---auaua |
008 |
|
930930r19921991mdua b f000 0 eng d |
035 |
⊔ |
⊔ |
‡asdr-ucla2524213
|
035 |
⊔ |
⊔ |
‡a2524213
|
035 |
⊔ |
⊔ |
‡907-AIM-8988
|
035 |
⊔ |
⊔ |
‡a(OCoLC)28915522
|
040 |
⊔ |
⊔ |
‡aMDU
‡cMDU
‡dVET
‡dCLU
|
245 |
0 |
0 |
‡aNew developments in the pharmacologic treatment of schizophrenia /
‡cguest editor, John M. Kane.
|
260 |
⊔ |
⊔ |
‡a[Rockville, MD] :
‡bNational Institute of Mental Health, U.S. Dept. of Health and Human Services, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration,
‡c[1992]
|
300 |
⊔ |
⊔ |
‡a165 p. :
‡bill. ;
‡c27 cm.
|
490 |
⊔ |
0 |
‡aDHHS publication ;
‡vno. (ADM) 92-1899
|
500 |
⊔ |
⊔ |
‡a"Reprinted from Schizophrenia bulletin, vol. 17, no. 2, 1991."
|
504 |
⊔ |
⊔ |
‡aIncludes bibliographical references.
|
538 |
⊔ |
⊔ |
‡aMode of access: Internet.
|
650 |
⊔ |
2 |
‡aSchizophrenia
‡xdrug therapy.
|
700 |
1 |
⊔ |
‡aKane, John M.,
‡d1945-
|
710 |
2 |
⊔ |
‡aNational Institute of Mental Health (U.S.)
|
730 |
0 |
⊔ |
‡aSchizophrenia bulletin.
|
CID |
⊔ |
⊔ |
‡a010389417
|
DAT |
0 |
⊔ |
‡a20080101125408.0
‡b20110718000000.0
|
DAT |
1 |
⊔ |
‡a20120815072711.0
‡b2024-09-07T17:53:04Z
|
DAT |
2 |
⊔ |
‡a2024-09-07T17:30:02Z
|
CAT |
⊔ |
⊔ |
‡aSDR-UCLA
‡dEX LIBRIS - VOYAGER
‡lloader.pl-001-001
|
FMT |
⊔ |
⊔ |
‡aBK
|
HOL |
⊔ |
⊔ |
‡0sdr-ucla2524213
‡auc1
‡bSDR
‡cUCLA
‡puc1.l0072015704
‡sUC
‡12524213
|
974 |
⊔ |
⊔ |
‡bUC
‡cUCLA
‡d20240907
‡sgoogle
‡uuc1.l0072015704
‡y1992
‡rpd
‡qbib
‡tUS fed doc
|